There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Marinus (NASDAQ:MRNS) and ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) with bullish sentiments.
Marinus (MRNS)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Marinus today and set a price target of $19. The company’s shares closed yesterday at $5.62.
Piros wrote:
“Given the compelling Phase 2 data announced in CDD, market size potential in PPD, and undervaluation relative to peers, we believe Marinus shares offer a compelling risk- reward profile. The company has three important data read-outs remaining in 4Q18, which we believe could become significant catalysts for the shares. Valuation Summary We arrive at our 12-month PT of $19/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder.”
According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -7.8% and a 38.5% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $16.75, representing a 198.0% upside. In a report issued on August 2, Mizuho Securities also maintained a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
ContraVir Pharmaceuticals Inc (CTRV)
Maxim Group analyst Jason McCarthy maintained a Buy rating on ContraVir Pharmaceuticals Inc today and set a price target of $3. The company’s shares closed yesterday at $0.84, close to its 52-week low of $0.69.
McCarthy commented:
“ContraVir provides an update on its ongoing clinical pipeline, as well as its business development efforts.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.8% and a 43.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Actinium Pharmaceuticals.
Currently, the analyst consensus on ContraVir Pharmaceuticals Inc is a Moderate Buy with an average price target of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
